date,title,source
Oct-17-18,5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage,InvestorPlace
Oct-17-18,"Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Oct-18-18,"Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018",Business Wire
Oct-19-18,Why Merck's Latest Success Means Trouble for Exelixis Inc.,Motley Fool
Oct-22-18,Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma,Business Wire
Oct-26-18,Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Exelixis,ACCESSWIRE
Oct-30-18,Exelixis (EXEL) to Report Q3 Earnings: What's in Store?,Zacks
Oct-31-18,Today's Research Reports on Trending Tickers: Exelixis and Sage Therapeutics,ACCESSWIRE
Nov-01-18,Exelixis: 3Q Earnings Snapshot,Associated Press
Nov-01-18,Exelixis Announces Third Quarter 2018 Financial Results and Provides Corporate Update,Business Wire
Nov-05-18,Exelixis Grabs Its Share of the Kidney-Cancer Treatment Market,Motley Fool
Nov-05-18,Edited Transcript of EXEL earnings conference call or presentation 1-Nov-18 9:00pm GMT,Thomson Reuters StreetEvents
Nov-05-18,Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Exelixis,ACCESSWIRE
Nov-06-18,"Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018",Business Wire
Nov-08-18,Can Exelixis (EXEL) Run Higher on Rising Earnings Estimates?,Zacks
Nov-12-18,Edited Transcript of EXEL earnings conference call or presentation 1-Nov-18 9:00pm GMT,Thomson Reuters StreetEvents
Nov-12-18,"Detailed Research: Economic Perspectives on Roku, Exelixis, Scientific Games, Boot Barn, Astronics, and AtriCure  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Nov-12-18,"Exelixis Revenues for Cabozantinib Continue to Grow, Clinical Development and Regulatory Progress",ACCESSWIRE
Nov-13-18,Edited Transcript of EXEL earnings conference call or presentation 1-Nov-18 9:00pm GMT,Thomson Reuters StreetEvents
Nov-14-18,"Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity",ACCESSWIRE
Nov-14-18,Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals,ACCESSWIRE
Nov-15-18,"Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx",Zacks
Nov-15-18,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",Benzinga
Nov-19-18,"Health Care Digest: Chelsea Clinton's shout out, Verily shelves 'smart lens' for diabetes, an East Bay biotech's hunt for employees and more",American City Business Journals
Nov-20-18,Exelixis Announces Webcasts of Investor Conference Presentations in November,Business Wire
Nov-23-18,Sarepta Stock More Than Doubles This Year So Far: Here's Why,Zacks
Nov-26-18,Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss,Zacks
Nov-26-18,3 Top Growth Stocks to Buy Right Now,Motley Fool
Nov-26-18,Is Exelixis Incs (NASDAQ:EXEL) CEO Being Overpaid?,Simply Wall St.
Nov-29-18,Biotech's Tackling Major Issues You Should Know,ACCESSWIRE
Dec-03-18,Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis,ACCESSWIRE
Dec-04-18,Why Exelixis (EXEL) Could Be Positioned for a Surge,Zacks
Dec-06-18,Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx,Zacks
Dec-06-18,Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis,ACCESSWIRE
